Unknown

Dataset Information

0

Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.


ABSTRACT:

Background

The clinical characteristics and treatment of patients who tested positive for COVID-19 after recovery remained elusive. Effective antiviral therapy is important for tackling these patients. We assessed the efficacy and safety of favipiravir for treating these patients.

Methods

This is a multicenter, open-label, randomized controlled trial in SARS-CoV-2 RNA re-positive patients. Patients were randomly assigned in a 2:1 ratio to receive either favipiravir, in addition to standard care, or standard care alone. The primary outcome was time to achieve a consecutive twice (at intervals of more than 24 h) negative RT-PCR result for SARS-CoV-2 RNA in nasopharyngeal swab and sputum sample.

Results

Between March 27 and May 9, 2020, 55 patients underwent randomization; 36 were assigned to the favipiravir group and 19 were assigned to the control group. Favipiravir group had a significantly shorter time from start of study treatment to negative nasopharyngeal swab and sputum than control group (median 17 vs. 26 days); hazard ratio 2.1 (95% CI [1.1-4.0], p = 0.038). The proportion of virus shedding in favipiravir group was higher than control group (80.6% [29/36] vs. 52.6% [10/19], p = 0.030, respectively). C-reactive protein decreased significantly after treatment in the favipiravir group (p = 0.016). The adverse events were generally mild and self-limiting.

Conclusion

Favipiravir was safe and superior to control in shortening the duration of viral shedding in SARS-CoV-2 RNA recurrent positive after discharge. However, a larger scale and randomized, double-blind, placebo-controlled trial is required to confirm our conclusion.

SUBMITTER: Zhao H 

PROVIDER: S-EPMC8059985 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7342044 | biostudies-literature
| S-EPMC7568126 | biostudies-literature
| S-EPMC8010778 | biostudies-literature
| S-EPMC7668212 | biostudies-literature
| S-EPMC7263509 | biostudies-literature
| S-EPMC7896311 | biostudies-literature
| S-EPMC8064419 | biostudies-literature
| S-EPMC7283767 | biostudies-literature
| S-EPMC8316887 | biostudies-literature
| S-EPMC4588424 | biostudies-literature